Vildagliptin is cost-effective in real-world: economic evaluation evidence from EDGE study

被引：0
|
作者：
Partha, G. [1 ]
Agrawal, R. [1 ]
Paldanius, P. M. [2 ]
Viana, R. [2 ]
机构：
[1] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India
[2] Novartis Pharma AG, Basel, Switzerland
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
993
引用
收藏
页码：S481 / S481
页数：1
相关论文
共 50 条
  • [41] Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets
    Murtojarvi, Mika
    Halkola, Anni S.
    Airola, Antti
    Laajala, Teemu D.
    Mirtti, Tuomas
    Aittokallio, Tero
    Pahikkala, Tapio
    INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 2020, 133
  • [42] Adalimumab, etanercept or infliximab: What is the most cost-effective anti-TNF4 therapy in RA in a real-world setting?
    Deeg, K.
    Ekelund, M.
    Runge, C.
    VALUE IN HEALTH, 2007, 10 (06) : A244 - A244
  • [43] Is This the Real Life? Real-World Evidence of Empagliflozin in Health Care Resource Utilization and Cost
    Harrington, Josephine
    Kang, Yu Mi
    McGuire, Darren K.
    DIABETES CARE, 2024, 47 (11) : 1897 - 1899
  • [44] The Clinical and Economic Impact of Delayed Reperfusion Therapy: Real-World Evidence
    Gioppatto, Silvio
    Prado, Paulo Sousa
    Elias, Mariana Araujo Lima
    de Carvalho, Veronica Homem
    Paiva, Caio Resende da Costa
    Alexim, Gustavo de Almeida
    Reis, Ricardo Torres Bispo
    Nogueira, Ana Claudia Cavalcante
    Soares, Alexandre Anderson de Sousa Munhoz
    Nadruz, Wilson
    de Carvalho, Luiz Sergio F.
    Sposito, Andrei C.
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2024, 121 (05)
  • [45] The use of real-world evidence in economic assessments of pharmaceuticals in the United States
    Lee, Woojung
    Dayer, Victoria
    Jiao, Boshen
    Carlson, Josh
    Devine, Beth
    Veenstra, David
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 306 - 306
  • [46] Use of real-world evidence in economic assessments of pharmaceuticals in the United States
    Lee, Woojung
    Dayer, Victoria
    Jiao, Boshen
    Carlson, Josh J.
    Devine, Beth
    Veenstra, David L.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (01): : 5 - 14
  • [47] Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation
    Vassall, Anna
    Siapka, Mariana
    Foster, Nicola
    Cunnama, Lucy
    Ramma, Lebogang
    Fielding, Katherine
    McCarthy, Kerrigan
    Churchyard, Gavin
    Grant, Alison
    Sinanovic, Edina
    LANCET GLOBAL HEALTH, 2017, 5 (07): : E710 - E719
  • [48] REAL-WORLD EVIDENCE ON ECONOMIC BURDEN OF MULTIPLE MYELOMA IN CHINA: A RETROSPECTIVE STUDY OF CLAIMS DATA
    Wang, J.
    Zhang, X.
    Liu, S.
    Sun, R.
    Liu, J.
    VALUE IN HEALTH, 2020, 23 : S51 - S51
  • [49] Obtaining real-world evidence: the Salford Lung Study
    New, John P.
    Bakerly, Nawar Diar
    Leather, David
    Woodcock, Ashley
    THORAX, 2014, 69 (12) : 1152 - 1154
  • [50] Real-world evidence for comprehensive evaluation of guselkumab in the treatment of psoriasis
    Thaci, Diamant
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025, 39 : 3 - 5
12345